Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice

Abstract Background Diabetes mellitus increases the excretion of urinary glucose from the renal glomeruli due to elevated blood glucose levels. In the renal tubules, SGLT2 is expressed and reabsorbs the excreted urinary glucose. In the pathogenesis of diabetes mellitus, glucose reabsorption by SGLT2...

Full description

Bibliographic Details
Main Authors: Ryo Bamba, Takuro Okamura, Yoshitaka Hashimoto, Saori Majima, Takafumi Senmaru, Emi Ushigome, Naoko Nakanishi, Mai Asano, Masahiro Yamazaki, Hiroshi Takakuwa, Masahide Hamaguchi, Michiaki Fukui
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
SGLT2 inhibitor
Sarcopenia
Muscle atrophy
Lipidome
Transcriptome
Online Access:https://doi.org/10.1002/jcsm.12814

Internet

https://doi.org/10.1002/jcsm.12814

Similar Items